The soluble interleukin 6 receptor (sIL-6R) circulates at elevated levels in various diseases. This suggests that inflammatory mediators control sIL-6R release. Through examination of human neutrophils, it was found that the acute phase reactant C-reactive protein (CRP) activates a threefold increase in sIL-6R production. Maximal release occurred after 30-60 min exposure to CRP (50 g/ml), and was mimicked by peptides corresponding to amino acid residues 174-185 and 201-206 of native CRP. A third peptide fragment (77-82) had no effect. Differential mRNA splicing did not account for the CRP-mediated release of sIL-6R, since this isoform was not detected in conditioned media. Furthermore, stimulation of neutrophils with CRP or with peptides 174-185 or 201-206 promoted a loss of membrane-bound IL-6R, suggesting release by proteolytic shedding. The metalloprotease inhibitor TAPI had only a marginal effect on CRP-mediated sIL-6R release, suggesting that shedding occurs via a mechanism distinct from that previously reported. It well established that IL-6 stimulates the acute phase expression of CRP. Our current findings demonstrate a novel relationship between these two mediators, since CRP may affect IL-6-mediated inflammatory events by enabling formation of the sIL-6R/IL-6 complex.
T he receptor complex that mediates the biological activities of IL-6 consists of two distinct membranebound glycoproteins, an 80-kD cognate receptor subunit (IL-6R, CD126) and a 130-kD signal transducing element (gp130) (1) . Although IL-6R expression is confined to select cell types, IL-6 can activate cells lacking the cognate receptor via a soluble IL-6 receptor (sIL-6R) (2) . Once bound to IL-6, the resulting sIL-6R/IL-6 complex acts as an agonist that is capable of activating cells through membrane-bound gp130. Since expression of gp130 is essentially ubiquitous, the sIL-6R/IL-6 complex has the potential to stimulate cell types that are not inherently responsive to IL-6 alone. Recent studies show that the sIL-6R/IL-6 complex can induce myocardial hypertrophy (3), cellular proliferation (4, 5) , and osteoclast formation (6) . In addition, the active complex has been reported to regulate leukocyte recruitment (7) , and to promote the proinflammatory stimulation of endothelial cells (7, 8) . These latter findings appear to contrast with the antiinflammatory properties assigned by some to IL-6 (9, 10) , and suggest that the sIL-6R/IL-6 complex not only potentiates IL-6 signaling, but may also modify its biological activities.
Two distinct isoforms of sIL-6R have been identified. The first is shed from the cell surface via proteolytic cleavage of the membrane-bound IL-6R (PC-sIL-6R [11, 12] ), whereas the second is secreted as the product of differential mRNA splicing (DS-sIL-6R [13, 14] ). The sIL-6R is present in the plasma of healthy individuals ( ‫ف‬ 25-35 ng/ ml), and these levels are significantly elevated in diseases such as rheumatoid arthritis, multiple myeloma, and T cell abnormalities such as AIDS and adult T cell leukemia (15) (16) (17) . The increased concentration of sIL-6R in these disease states suggests that some inflammatory event either stimulates release of PC-sIL-6R, or increases the expression of DS-sIL-6R. Since the inflammatory potential of IL-6 is modulated through binding the sIL-6R, identifying physiological mediators of sIL-6R generation is of central importance to understanding the significance of this soluble receptor in disease.
Bacterial pore-forming toxins (18) and FMLP (8) are known to activate generation of PC-sIL-6R, whereas oncostatin-M was recently shown to stimulate the release of DS-sIL-6R from a human hepatoma cell line (19) . However, to date no endogenously produced activator of PC-sIL-6R shedding has been identified. In the present study, C-reactive protein (CRP), at concentrations likely to be encountered during an acute phase response, was found to provoke release of the membrane-bound IL-6R from human neutrophils. Thus, CRP has the potential to influence the inflammatory properties of IL-6 through facilitating formation of the sIL-6R/IL-6 complex.
Materials and Methods
Materials. Culture reagents were obtained from GIBCO BRL, and purified human CRP from Calbiochem-Novabiochem Corp. Peptides corresponding to CRP amino acid residues 77-82 (VGGSEI), 174-185 (IYLGGPFSPNVL), and 201-206 (KPQLWP) were from Sigma Chemical Co. Biotinylated antihuman IL-6R antibody (BAF-227) was from R&D Systems. Anti-DS-sIL-6R mAb (2F3) was generated as described previously (20) . Dr. R.A. Black (Immunex Corp.) provided the TNF-␣ -protease inhibitor, TAPI. Lymphoprep was from Nycomed Pharma, and ImmunoPure 3,3 Ј , 5,5 Ј -tetramethylbenzidine (TMB) from Pierce Chemical Co.
Isolation of Human Neutrophils. Venous blood (20 ml) was obtained by antecubital venipuncture from nonsmoking healthy individuals (aged 26-54), mixed with an equal volume of 2% (wt/ vol) dextran/0.8% (wt/vol) trisodium citrate in PBS (pH 7.4), and erythrocytes were allowed to sediment. Plasma was collected, underlayered with Lymphoprep (2:1 [vol/vol] plasma/Lymphoprep), and centrifuged at 4 Њ C for 20 min at 800 g . The neutrophilcontaining pellet was collected, and contaminating erythrocytes were removed by hypotonic lysis. Neutrophil preparations were found to be Ͼ 95% pure as assessed by differential Wright staining. Before use, neutrophils were resuspended in serum-free RPMI 1640 containing 2 mM l -glutamine, 100 U/ml penicillin, and 100 g/ml streptomycin.
Determination of sIL-6R Production. Neutrophils (2 ϫ 10 6 cells) were treated as described in the figure legends. Culture medium was harvested and stored at Ϫ 80 Њ C until required. Concentration of sIL-6R was determined using an ELISA procedure. Microtiter 96-well plates were coated with 10 g/ml antihuman IL-6R mAb (mAb 17.1; reference 21) and blocked at 4 Њ C with 0.5% BSA. sIL-6R standards and unknowns were added and incubated at room temperature for 2 h. To detect bound sIL-6R, biotinylated anti-human IL-6R antibody (50 ng/ml BAF-227) was added for 2 h at room temperature, followed by a 20-min incubation with horseradish peroxidase-conjugated streptavidin. Plates were washed between each step with PBS containing 0.1% Tween 20. Peroxidase activity was determined using TMB as a substrate. The reaction was stopped with 1.8 M H 2 SO 4 , and absorbance was measured at 450 nm. To detect DS-sIL-6R, the capture antibody was replaced with 20 g/ml anti-DS-sIL-6R antibody (mAb 2F3), and ELISA was performed as described using baculovirus-expressed DS-sIL-6R as a standard (20) . The lower limit of detection for sIL-6R and DS-sIL-6R was 10 and 50 pg/ml, respectively.
Flow Cytometry. Loss of IL-6R expression from the neutrophil cell surface after stimulation was monitored by cytofluorometry (FACScan ® ; Becton Dickinson) as described (20) . Values are expressed as the percent reduction in mean fluorescence units (MFU) from nonstimulated control cells: MFU ϭ (FU experimental Ϫ FU autofluorescence )/(FU control Ϫ FU autofluorescence ).
Statistical Analysis. Statistical analysis was performed using Student's t test incorporated into the SigmaPlot (version 2.01) graphics program. A P Ͻ 0.05 indicated a statistically significant difference.
Results

C-reactive Protein Stimulates Production of sIL-6R by Human Neutrophils.
Examination of human neutrophils obtained from 10 independent donors showed that CRP activates sIL-6R production (Fig. 1) . In each case, basal sIL-6R release was significantly increased ( P Ͻ 0.0001) after exposure to 50 g/ml CRP, with the extent of sIL-6R production ranging between 86 and 234 pg/ml after CRP stimulation compared with 21-84 pg/ml for controls. On average, CRP resulted in a 3.06 Ϯ 1.03-fold induction of sIL-6R levels (Fig. 1 B) . In contrast, activation of human neutrophils with IL-4 or IL-10 had no effect on sIL-6R generation (data not shown). As shown in Fig. 2 A, production of sIL-6R increased rapidly, with optimal release occurring between 30 and 60 min after CRP addition. Generation of sIL-6R was also dose-dependent, with 50 g/ml CRP inducing a maximal response (Fig. 2 B) . Release of the sIL-6R in response to a single exposure to CRP was transient, since levels returned to baseline within 4-5 h after stimulation. Addition of a second CRP dose 2 h after the initial CRP stimulation did not further enhance production (data not shown).
Peptides Derived from CRP Activate sIL-6R Production. Neutrophil stimulation has been shown to activate the cleavage of native CRP into biologically active peptide fragments (A) Human neutrophils (2 ϫ 10 6 cells) from 10 independent donors were stimulated at 37ЊC, 5% CO 2 with 50 g/ml CRP for 30 min, and the concentration of sIL-6R in culture medium was determined by ELISA. Horizontal bars represent the mean sIL-6R concentration for control (43 pg/ml) and CRP-activated (129 pg/ml) neutrophils. The CRP-induced release of sIL-6R was statistically significant (P Ͻ 0.0001) as determined by Student's t test. (B) The magnitude of CRP-induced sIL-6R production is shown for each donor. For controls, the mean concentration of 43 pg/ml was set to 1 and compared with the nonstimulated release for each donor. Values are expressed as mean fold induction Ϯ SD (n ϭ 10). (22) . In particular, peptides corresponding to amino acid residues 77-82, 174-185, and 201-206 profoundly influence neutrophil responses (23, 24) . Accordingly, human neutrophils were incubated with each of these peptides and their capacity to augment sIL-6R production was determined. As shown in Fig. 3 , (174-185)CRP and (201-206)CRP stimulated sIL-6R production in a dose-dependent manner, whereas peptide (77-82)CRP had little or no effect.
CRP-activated Release of sIL-6R Occurs via Loss of the Cognate IL-6R.
The sIL-6R can be released through proteolytic shedding of the cognate IL-6R or secreted as the product of differential IL-6R mRNA splicing (11) (12) (13) (14) . Flow cytometry using neutrophils from three separate donors showed that a 30-min exposure to 100 g/ml native CRP resulted in a 44 Ϯ 2.5% loss of the cognate IL-6R. Similarly, 100 g/ml (174-185)CRP and (201-206)CRP stimulated a 33 Ϯ 6.2% and 24 Ϯ 0.3% reduction in the surface expression of IL-6R, respectively, whereas peptide (77-82)CRP had little effect (data not shown). This indicates a role for CRP in the activation of IL-6R shedding. To verify this conclusion, the concentration of DS-sIL-6R was determined in conditioned media from CRP-activated neutrophils, using an antibody specific for the unique COOH-terminal amino acid sequence (GSRRRGSCGL) of DS-sIL-6R (20) . As shown in Table I , no detectable level of DS-sIL-6R could be identified either before or after CRP stimulation. Interestingly, no correlation could be established between elevated systemic CRP concentrations and DS-sIL-6R levels in patients suffering from various clinical disorders (Horiuchi, S., and N. Yamamoto, unpublished data).
Partial Inhibition of sIL-6R Production by TAPI. Hydroxamic acid-based metalloprotease inhibitors such as TAPI are known to prevent shedding of various cell surface proteins (25) (26) (27) , including the IL-6R (12, 20) . Surprisingly, the CRP-induced release of sIL-6R by neutrophils was only partially blocked by TAPI ( ‫ف‬ 20-25%; Fig. 4 ). Consistent with previous reports (12, 20) , TAPI inhibited 70-75% of the phorbol ester-stimulated sIL-6R production by monocytic THP-1 cells (data not shown). Thus, the mechanism responsible for CRP-induced release of the cognate IL-6R from human neutrophils may be distinct from that described for monocytic cells.
Discussion
Elevated levels of the sIL-6R have been associated with the pathology of several disease states. This implies that production of the sIL-6R is increased as part of the inflam- SD (n ϭ 3) . Release of sIL-6R in response to 50 g/ml CRP was 177.4 Ϯ 6.5 pg/ml. matory response. However, little is known regarding the factors that might regulate sIL-6R generation. In this study, physiological concentrations of native CRP and biologically relevant CRP-derived peptides were found to stimulate sIL-6R production by human neutrophils. Release of this soluble receptor was rapidly induced after CRP treatment and occurred via shedding of the cognate IL-6R from the cell surface. C-reactive protein represents the first known endogenous activator of this process. The observation that release of sIL-6R is only partially prevented by the hydroxamic acid-based metalloprotease inhibitor TAPI is of particular interest, since IL-6R shedding in response to phorbol esters and ionomycin has been shown to be prevented by this agent (12, 20) . Thus, in neutrophils, shedding of the IL-6R presumably occurs through a unique proteolytic mechanism. Indeed, under certain experimental conditions the phorbol ester-induced shedding of L-selectin (CD62L) from human neutrophils has also been found to be only partially susceptible to a TAPI homologue (27) .
In general, plasma CRP levels correlate with severity of inflammatory diseases. During the onset of inflammation or tissue injury, plasma concentrations of CRP are dramatically elevated from ‫ف‬ 1 g/ml in healthy individuals to as much as 500 g/ml during the acute phase response (28) .
In vitro studies have shown that control of this response is primarily regulated by IL-6 (29). More recently, human CRP-transgenic mice were used to verify in vivo that IL-6 is absolutely required for the induced expression of CRP during an inflammatory acute phase response (30) . Our current findings show that this relationship between IL-6 and CRP is more complex than previously thought, since IL-6R shedding in response to CRP likely contributes to formation of the agonistic sIL-6R/IL-6 complex. Thus, CRP acts not only as an acute phase reactant, but it may have a profound effect on distal IL-6-mediated events that occur during the inflammatory process. Indeed, CRP levels in several diseases have been found to correlate with those of sIL-6R (31) (32) (33) .
It is now recognized that CRP plays a significant role in host defense against pathogens (34) . C-reactive protein also binds to specific receptors on human neutrophils and diminishes neutrophil responses, such as chemotaxis (35) and the activation of superoxide generation and degranulation by chemoattractants (36) . In addition, CRP prevents neutrophil adhesion to endothelial cells via induction of L-selectin (CD62L) shedding (37) . Consistent with these findings, in vivo studies have shown that CRP abates neutrophil recruitment in models of inflammation (38, 39) . Taken together, these data indicate that CRP also performs an antiinflammatory function. It is therefore noteworthy that the sIL-6R/IL-6 complex has been shown to regulate proinflammatory activation of endothelial cells and to promote neutrophil recruitment (7, 8) . In agreement with these findings, it has been observed that the extent of neutrophil infiltration into arthritic joints correlates with elevated sIL-6R levels in synovial fluid (40) . It is conceivable that CRP may perform a pivotal role during inflammation by modulating the rate of neutrophil recruitment. It is also highly likely that CRP represents only one endogenous activator of IL-6R shedding, whereas release of DS-sIL-6R may also contribute to the overall properties of sIL-6R (13, 14, 18) .
Previous studies have shown that peptides spanning residues 77-82 and 201-206 of the native CRP molecule block neutrophil superoxide generation and chemotaxis (23, 24) , whereas peptide fragment 177-182 enhances cytokine/chemokine production and the tumoricidal activity of monocytic cells (41) . Structure/function investigations of native CRP (for a review, see reference 34) reveal that amino acids 77-82 reside within the phosphocholine (PCh)-binding site of the CRP molecule, whereas residues 174-185 and 201-206 form parts of the walls of a deep cleft on the opposite face of the CRP protomer. The shallow end of this cleft represents the C1q-binding site of CRP (34) , whereas residues 175-179 are important for Fc ␥ -R1 binding (42) . Interestingly, in the present study, CRP peptides 174-185 and 201-206 effectively augmented sIL-6R production by human neutrophils. However, release was not observed in response to residues 77-82. Similarly, CRP peptides 174-185 and 201-206, but not 77-82, were found to mediate L-selectin shedding (37) . These data argue that the ability of CRP to stimulate IL-6R and L-selectin shedding from neutrophils involves Neutrophils (2 ϫ 10 6 cells) were stimulated with CRP for 45 min, and levels of total sIL-6R and DS-sIL-6R in conditioned medium were quantified (see Materials and Methods). Values represent the mean Ϯ SD ( n ϭ 3). In the case of DS-sIL-6R, levels were below the limit of detection for the ELISA (ϽLD). *P Ͻ 0.05; ‡ P Ͻ0.01 vs. nonstimulated control. interaction via the C1q/Fcg-R1 binding motif of CRP, and does not involve the PCh-binding site. Support for this concept is derived from the fact that disruption of the Ca 2ϩ -dependent interaction of PCh with CRP (34) through the addition of EDTA had no effect on the CRPinduced release of sIL-6R (data not shown). Although neutrophils express relatively high levels of the cognate IL-6R, IL-6 signaling in these cells is poorly defined and appears to evoke only weak biological activities (43, 44) . However, shedding of the IL-6R from human neutrophils has been shown to activate endothelial cells (8) . As a result, expression of the IL-6R on neutrophils may primarily serve as an inducible source of sIL-6R. Thus, the activated shedding of the IL-6R from neutrophils may indirectly propagate the inflammatory response via stimulation of resident tissue cells by the sIL-6R/IL-6 complex.
